Enanta Pharmaceuticals Inc (ENTA)

Form 424B5 - Prospectus [Rule 424(b)(5)]
July 02 2026 - 4:54PM

https://investorshub.advfn.com/stock-market/NASDAQ/enanta-pharmaceuticals-ENTA/stock-news/98860515/form-424b5-prospectus-rule-424b5

Additional info re: Dew's post -

Enanta Pharmaceuticals intends to offer and sell up to $75,000,000 of its common stock through an Open Market Sale (sales agreement) with Jefferies LLC as sales agent under an at-the-market offering structure. The sales agreement permits sales from time to time through Jefferies, which may receive commissions up to 3.0% of aggregate gross proceeds. The prospectus supplement uses an assumed offering price of $14.77 per share (the last reported sale price on July 1, 2026) to illustrate an aggregate issuance of 5,077,860 shares and presents illustrative dilution and as-adjusted net tangible book value. Shares outstanding are shown as 29,061,152 as of March 31, 2026. Sales may occur at varying prices and quantities; Jefferies is not required to sell any specific amount and will act using commercially reasonable efforts on mutually agreed terms.

Financing flexibility supports ongoing clinical programs but creates potential dilution over time.

The offering is structured to provide rolling access to capital to fund trials including zelicapavir Phase 2b/3 and EDP-978 Phase 1, per the supplement. Illustrative use of proceeds includes clinical, R&D and general corporate purposes.

Because sales occur at market prices and quantities are variable, the ultimate dilutive impact will depend on when and at what prices shares are sold; management discretion over proceeds use is explicit in the filing.

https://www.stocktitan.net/sec-filings/ENTA/424b5-enanta-pharmaceuticals-inc-prospectus-supplement-debt-securitie-9ed12d72304b.html

ENTA establishes $75M at-the-market financing facility:

https://www.sec.gov/ix?doc=/Archives/edgar/data/1177648/000119312526294837/d123412d8k.htm On July 2, 2026, Enanta Pharmaceuticals, Inc. …entered into an Open Market Sale Agreement…with Jefferies LLC, as sales agent, …pursuant to which the Corporation may offer and sell shares of its common stock… from time to time through the Agent. ENTA decides when—and if—to use this ATM facility. (In many cases, companies establish ATM facilities but never draw on them.)

The placement fee for any shares actually sold through the ATM is 3%.

Understand, but I see the current price / SNY share having already priced in these lowered expectations.
As to ENTA, no doubt more and more investors / institutions are seeing ENTA as undervalued here.

prophetic

They are also heavily reliant on Dupixent and the COM patent expires in early 2031 so not that far off
Dupixent may also lose share to long acting injectables and orals targeting that pathway

MAVRET web site- check it out



https://www.facebook.com/MAVYRET/about FACEBOOK

O/T - Sanofi

Here's Y:

Sanofi's stock has faced downward pressure due to a combination of pipeline setbacks, competitive threats to blockbuster vaccines, and leadership changes.

Key factors pressuring the stock include:

Pipeline and Clinical Concerns: Disappointing late-stage trial data and FDA review delays for key pipeline candidates, such as the multiple sclerosis drug tolebrutinib, have heightened investor concerns about the company's ability to replace aging drugs.

Intense Vaccine Competition: Sales for Sanofi’s flu vaccines have declined due to increasing pricing and market competition. Additionally, their RSV preventative, Beyfortus, is facing growing challenges from recently launched competitor monoclonal antibodies.

Leadership Transition: Sudden executive changes, including the abrupt ouster of former CEO Paul Hudson over stalled turnaround efforts, brought added volatility. New CEO Belén Garijo took over in late April 2026, putting investor focus squarely on long-term R&D over near-term profits.

Analyst Downgrades: Wall Street firms like Morgan Stanley have downgraded Sanofi shares, citing a lack of significant, major growth catalysts in the near-term pipeline before 2027.

OT Why is Sanofi so unloved?

Enanta Pharmaceuticals (NASDAQ: ENTA) has around 2.27 million shares sold short, representing roughly 8.84% to 9.07% of the total public float. With an average daily trading volume, it takes approximately 11.0 days for traders to cover these positions.

I can see $18+ if there is a short squeeze.

Keep 'em comin' -

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 2500 Growth Benchmark
Published on 06/29/2026 at 03:22 pm EDT

https://www.marketscreener.com/news/enanta-pharmaceuticals-inc-nasdaqgs-enta-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f221

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark
Published on 06/29/2026 at 04:43 pm EDT

https://www.marketscreener.com/news/enanta-pharmaceuticals-inc-nasdaqgs-enta-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd81f721

EVMN—(-40%)—fails phase-2b in CSU:

https://www.businesswire.com/news/home/20260629470075/en/Evommune-Announces-Top-line-Results-from-EVO756-Phase-2b-Trial-in-Moderate-to-Severe-Chronic-Spontaneous-Urticaria

Although the PR says EVMN will continue to test EVO756 in other indications, it looks likely that ENTA has one fewer competitor in the oral MRGPRX2 arena.

That “article” was likely AI generated because it came out right “after” ENTA issued the 8-k reporting that they lost the appeal. Example of an AI hallucination.

Another Russell addition -

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark
Published on 06/29/2026 at 12:08 am EDT

https://www.marketscreener.com/news/enanta-pharmaceuticals-inc-nasdaqgs-enta-added-to-russell-3000e-growth-benchmark-ce7f5fdeda88f523

Is Enanta still pursuing this in the US?

We lost the appeal in the U.S. - fait de complete

Europe might be a win by September.

Enanta Files Appeal in Ongoing Patent Dispute With Pfizer Over Paxlovid
Published on 06/24/2026 at 06:23 am EDT

Saw this in the link but I have not seen it anywhere else. Is Enanta still pursuing this in the US? They lost the first appeal on June 23.

Addendum:

AI Overview

For a publicly traded company, being included in a major FTSE Russell Growth Index is highly important because it drives structural liquidity, broadens investor visibility, and triggers mandatory buying from institutional and passive funds.

Key Benefits of Index InclusionPassive Fund Inflows: Trillions of dollars in index-tracking Exchange-Traded Funds (ETFs) and mutual funds are mandated to buy your stock to replicate the index's performance. This surge in demand creates liquidity and often stabilizes the share price.Increased Institutional Ownership:

Actively managed portfolios use Russell US Indexes as benchmarks. Being listed puts your company on the radar of institutional investors who might not have discovered your stock otherwise.

Visibility and Prestige: Joining a benchmark like the Russell 1000 Growth Index serves as a stamp of approval, signaling to the market that your company is demonstrating reliable market capitalization and business expansion.

Thanks Rocky3 -

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 2000 Growth Benchmark

Published on 06/29/2026 at 06:40 am EDT

https://www.marketscreener.com/news/enanta-pharmaceuticals-inc-nasdaqgs-enta-added-to-russell-2000-growth-benchmark-ce7f5fdede8fff25

$15 next week…

Isn't Russell re-balancing happening now? My guess is that huge number of stocks had large number of shares traded at close or in after-market.

Busy ending 20 minutes -

Last Trade Size - 483,719

Block trade count - 5

Total shares traded - 926,451

Shorts buying back?

Unless the inventors actually meant c2-c12 exactly as written in the Spec. This was a bad case from the get-go. Rather Jay and Tara focus on securing the RSV Partnership without further delay.

More bad press -

Pfizer’s US Paxlovid patent fight turns on a single error

https://www.lifesciencesipreview.com/americas/pfizers-us-paxlovid-patent-fight-turns-on-a-single-error

Stupid is as Stupid does - Forest Gump

**You might reckon that ENANTA can fire and/or sue those (attorneys??) responsible for this disastrous, financial oversight!

Wholeheartedly agree with all your points. They pissed away a lot of money and legal fees in my opinion. In the end, they got what they deserved for being sloppy.  FWIW, I am still bullish on this investment with their RSV program and their immunology programs.

The provisional - separately from the C2-12 - does mention structures that include one to four etc alkyl groups, so there was a discrepancy. The C2-12 was carried over repeatedly however. ENTA expert said thsi was likely a cut and paste error carried over. The court in the end felt there was enough uncertainty to judge what was intended in the provisional and that they can make the decision it shouldn't go to a jury
c'est la vie
Between you and me now that this is behind us it is much more likely to be a typo that a true intent to omit a C1 alkyl group and remedy that after the structure of paxlovid was disclosed publicly bc writing subscripts is more of an effort so cutting and pasting in a document is just the way to go, but more importantly why on earth would you ever want to narrow your patent by one carbon group?! You never want too broad a patent that can be challenged, but we are not talking about a significant broadening that would in and of itself pose a challenge. I think if this did come to a jury a good lawyer could convince them of the type of typo that likely occurred, but ENTA won't get that chance. Super sloppy if this was indeed what happened and very costly.

For clarity purposes -

500M typo (most likely) - DEWOPHILE is CORRECT

Provisional Typo Spoils Priority Date
June 24, 2026
by Dennis Crouch

A seeming typo in Enanta's provisional application left the resulting patent invalid. In Enanta Pharmaceuticals, Inc. v. Pfizer, Inc., No. 2025-1427 (Fed. Cir. June 23, 2026), the Federal Circuit affirmed summary judgment that the claims of its US11358953 are anticipated by intervening prior art because the priority filing did not sufficiently describe the claimed invention. Enanta's provisional application listed a substituent as NHC(O)-C2-C12-alkyl (showing a two to twelve carbon range). The issued patent listed that same substituent as NHC(O)-C1-C12-alkyl, adding the one-carbon member. That one-carbon version described nirmatrelvir, the protease inhibitor Pfizer disclosed first in April 2021 and later began selling as Paxlovid. Because the provisional never disclosed the one-carbon species, the patent could not claim the provisional's July 2020 priority date, and Pfizer's intervening disclosure anticipated the claims.

Enanta argued that the "C2" in its provisional was an obvious typographical error that should have read "C1," so correcting it added no new matter. The Federal Circuit focused on the question of written description and priority: did the provisional's two-to-twelve carbon range support, under 35 U.S.C. 112, the one-carbon species the patent later claimed? Does "2" describe "1"? The court answered no, and it applied the written description standard de novo even though the district court had treated the case as one about its power to correct an error.

Subscription required to read additional:
https://patentlyo.com/patent/2026/06/provisional-typo-spoils-priority-date.html

the data for zeli was strong enough in HR adults that I don't know if a second drug trying to best an already very good drug (probably) is a wise spend of capital
if anything there is more room for improvement in peds based on that data set. Note that they are not running behind shionogi in peds since they have nothing in that indication running at the moment
my 2 cents

H.C. Wainwright reiterates Enanta stock rating on FDA alignment - June 23, 2026

H.C. Wainwright reiterated a Buy rating and $20.00 price target on Enanta Pharmaceuticals (NASDAQ:ENTA). The stock currently trades at $13.37, representing nearly 50% upside to the analyst’s target. Shares surged 11% over the past week following the FDA news, contributing to an impressive 88% gain over the past year.

The firm views Enanta’s recent FDA alignment on zelicapavir as an important positive development that meaningfully reduces regulatory uncertainty and establishes a clear path toward registration in RSV.

Following discussions with the agency, the company received agreement to advance zelicapavir through a single Phase 2b/3 study in high-risk adult RSV patients rather than conducting two independent Phase 3 trials.

H.C. Wainwright said the outcome compares favorably with investor expectations and reflects the strength of the efficacy signal observed in the previously reported RSVHR study.

The agreement lowers the expected development burden and provides a more efficient path to market while preserving the opportunity to generate meaningful clinical data on both symptom resolution and hospitalization outcomes.

In other recent news, Enanta Pharmaceuticals Inc. has announced plans to advance its RSV drug, zelicapavir, into late-stage clinical trials. The company will initiate a registrational Phase 2b/3 trial in high-risk adults in the fourth quarter of 2026, with topline Phase 2b data expected in 2027. Enanta also plans to start a Phase 2b trial for pediatric patients in the third quarter of 2026. Additionally, Enanta has dosed the first participant in a Phase 1 trial of EDP-978, an oral KIT inhibitor for chronic urticaria and other mast cell-driven diseases. This trial will assess the safety and pharmacokinetics of EDP-978 in approximately 98 healthy adult volunteers.

https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-enanta-stock-rating-on-fda-alignment-93CH-4755287

Best wishes on your recovery, Vin…

I would have loved a deal already, especially one that would have avoided a raise at 10 dollars. That said right now the type of deal you might pursue very well may depend on a few factors that are around the corner. The two lawsuits, and the first clinical readout in immunology. That might give you a better sense of your current resources, and future needs if you would prefer to put more development dollars in immunology or not. So a year ago or even 7-8 months ago when you had the adult readout and what I thought was a data set that gives a fairly clear line of sight to commercialization in an indication partnering made a lot of sense. Right now I don't see the rush

Edit: one advantage of pushing a partnership right now versus waiting a bit is moving the L inhibitor in parallel into trials in case that MOA proves superior. That is something a partner easily could do whereas for ENTA it is stretching their budget further

dewophile, agree completely. My only possible area of difference is doesn't ENTA have enough money to push their L inhibitor in a smaller phase 2 in adult general population rather than high risk. That might ameliorate some risk posed by Shinogi's L inhibitor and keep it on track without directly competing with Zelli.

Echoes of EDP-235.

As Dew said, Zeli isn't close to what happened with EDP-235 as Zeli not only completed phase 2 with stellar results for high risk but has been given the go ahead given for phase 3.EDP-235 only had early stage trial data.. Add in that Paxlovid was already on the market so there was a big pharma competitor. Add in that by the time EDP-235 was ready for phase 2 or phase 3, Covid vaccines became widespread, making it far more difficult to run big trials for approval.

I have been a bit out of it as I had a hip replacement 4 weeks ago and am now far better. Pretty miraculous as I left the hospital the same day as surgery and walked out of surgery using a walker. I am now walking without a cane. Not yet back to full strength but my hip pain stopped the day of surgery and is gone.

I don't know whether it was a typo or not, but what I have said before was that I was concerned that ENTA was listening to their lawyers and instead should have dropped the litigation after the summary judgement. That could have saved money and attention toward the RSV clinical trials. Which, by the way, IMO should have advanced EDP-323 rather than Zeli. We know that 323 is most likely the better drug, they can't afford multiple shots at the goal, and Shionogi's S-337395 may now leapfrog them.

I am still optimistic that their immunology development will pay off, they are good at developing drugs that work. They just need to stop scoring own goals...

Enablers benefit from those they coddle. Supposedly, the best parasites do not result in total destruction of their hosts. Good to know that not everyone will get away with claiming something, incorrectly describing it and shouting metoo!

FOLEY HOAG - May 11 Appeal: Did you forget your train of thought? YES

ENTA Shareholders: Did you forget your paycheck? NO

I assume Foley Hoag were happy that a loss was baked into the stock price. This appeal had a next to nothing chance of being overturned so the only real beneficiaries were the lawyers.

500M typo (most likely)
oh well
glad to see the stock taking this in stride - I mean we all thought it was baked in already and the market reaction confirms that

Reposting From WorstLuck
PFE/ENTA No surprises. 

https://www.courtlistener.com/opinion/10878465/enanta-pharmaceuticals-inc-v-pfizer-inc/?order_by=score+desc&q=Enanta+Pfizer+Federal+Circuit&type=o

CONCLUSION 
We have considered Enanta’s remaining arguments 
but find them unpersuasive. For the foregoing reasons, we 
affirm. 
AFFIRMED

ENTA loses CAFC appeal in Paxlovid patent-infringement case:

https://www.courtlistener.com/opinion/10878465/enanta-pharmaceuticals-inc-v-pfizer-inc

The European case remains pending.

The European Commission’s rubber-stamping of the CHMP’s Mavyret approval for acute HCV rook only one month (#msg-177632231), which is somewhat faster than usual.

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C VirusJune 23, 2026 5:10 AM
Business Wire MAVIRET® (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection Approval Allows Providers to Treat HCV Patients Immediately at Time of Diagnosis; Early Diagnosis and Treatment Help Reduce Transmission, Long-Term Liver-Related Complications, and Support HCV Elimination Efforts Glecaprevir, One of the Two Direct-Acting Antivirals in MAVIRET®, was Discovered by Enanta and Developed and Commercialized by AbbVie Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older. MAVIRET is now the only treatment approved in the European Union (EU) for both acute and chronic HCV infection. “The European Commission’s approval of MAVIRET for acute HCV infection is a meaningful step for the more than 12 million individuals in Europe living with HCV, by enabling earlier treatment and supporting timely intervention at a stage when the disease may be asymptomatic and can go undetected,” said Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. “Given acute HCV is typically diagnosed incidentally, starting treatment before a patient has advanced to chronic HCV can be difficult. Today’s approval supports public health efforts by accelerating treatment, reducing transmission and addressing unmet need. We take pride in the role our discovery of glecaprevir has played in bringing forward a therapy that continues to benefit HCV patients worldwide. We are pleased that AbbVie continues to collaborate with global regulatory authorities to support access to MAVIRET for people who have acute HCV infection.” The EU approval for acute HCV infection was supported by data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of MAVIRET eight-week treatment in patients with acute HCV infection.1 The study results showed MAVIRET to be a highly efficacious treatment for people with acute HCV.1 The majority of the adverse events reported were mild or moderate in severity.1 The most common adverse events were fatigue, diarrhea, headache, and asthenia.1 HCV is a highly infectious, blood-borne disease that affects the liver and if left untreated can lead to serious complications, including liver cirrhosis and cancer.2 Acute HCV infection is frequently asymptomatic and many people remain unaware of the infection until it has progressed to a later stage.2 Clinical guidelines support treating nearly all individuals with acute or chronic HCV.3 Globally, hepatitis C imposes a substantial health and economic burden4, underscoring the importance of early diagnosis and timely access to treatment. About the Phase 3 M20-350 Study1
The multicenter, single-arm prospective Phase 3 M20-350 clinical trial was designed to evaluate the safety and efficacy of MAVIRET (glecaprevir/pibrentasvir) eight-week treatment in adults and adolescent participants aged 12 years and older with acute HCV infection. The study enrolled 286 treatment-naïve adult patients with acute HCV infection across 70 locations globally. Patients received oral tablets of MAVIRET once daily for eight weeks and were followed for 12 weeks after the end of treatment. The primary endpoint was the percentage of patients with sustained virological response 12 weeks post-treatment (SVR12) in the intent-to-treat population (ITT). The study met its primary endpoint, with 96.2% of patients in the ITT population achieving SVR12 (p

Addendum—In the whole time I've been following ENTA I don't think they ever missed a projected clinical milestone that they announced to investors.

Well said dewophile.

I would have loved a deal already, especially one that would have avoided a raise at 10 dollars. That said right now the type of deal you might pursue very well may depend on a few factors that are around the corner. The two lawsuits, and the first clinical readout in immunology. That might give you a better sense of your current resources, and future needs if you would prefer to put more development dollars in immunology or not. So a year ago or even 7-8 months ago when you had the adult readout and what I thought was a data set that gives a fairly clear line of sight to commercialization in an indication partnering made a lot of sense. Right now I don't see the rush

Edit: one advantage of pushing a partnership right now versus waiting a bit is moving the L inhibitor in parallel into trials in case that MOA proves superior. That is something a partner easily could do whereas for ENTA it is stretching their budget further

They are collaborating with the Penta foundation for the pediatrics, and Chiang Mai university for the high risk. With good results they will be in a stronger position to partner.

Echoes of EDP-235. Not at all. EDP-235 never reached the stage where ENTA announced a phase-3 program and trial design as has now been done for Zelicapavir.

Magical thinking, Dew. Echoes of EDP-235.

Jay has made countless promises regarding a future partnership. He reminds me of Bobby Moore and the Rhythm and Aces song. Searching , searching for my baby ! I know I’m dating myself but come on Jay !! Nobody wants a bad deal but enough is enough.

It’s time for Big Pharma to BUY ENTA!

You can… ask AI what has changed since last slide deck. AI also will also explain why the changes were made. See #msg-177716832. I trust myself more than I trust a chatbot, LOL.

ENTA’s updated corporate slides (6/18/26)

https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

The new slide deck has several consequential additions and simplifications relative to the previous (5/11/26) version:

• Slide 7, “Multi-Billion Dollar Global Market Opportunity for an RSV Antiviral” is new.

• Slide 10, which shows results of the completed (standalone) phase-2b for Zelicapavir in high-risk adults, has been simplified to show only the endpoints that are pertinent to the phase-2/3 registrational trial announced in today’s PR (see next bullet item).

• Slide 11 shows the trial design and primary/secondary endpoints of the Zelicapavir phase-2/3 registrational trial. It supersedes old slides 11-14.

• Slides 12-13 depict the Zelicapavir program in pediatric patients, including the trial design and primary/secondary endpoints of the phase-2b pediatric trial. These slides supersede old slides 15-18.

• Slide 15, which depicts the results of the EDP-323 “challenge” study, condenses the info from old slides 20-22, omitting the PCR measurement of viral load in favor of the more consequential viral-culture assay.

• Slide 25, which shows the potency and selectivity of EDP-978 (KIT inhibitor), condenses the info from old slides 32-33.

• Slide 29, which shows the potency and selectivity of EDP-3903 (STAT6 inhibitor), condenses the info old slides 37-38.

• Old slide 44, which pertains to ENTA’s MRGPRX2 program, has been deleted. This slide had a glaring typo (I’ll make this a quiz!), although there may be another reason it was removed from the deck. The new slide deck still has four slides (34-37) describing the MRGPRX2 program.

• Last but not least, slide 38 on 2026 clinical catalysts now has a check mark for the item, “FDA End-of-Phase 2 meeting on adult pivotal study design & registration path in 2Q 2026.”